Get notified when QURE files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Passive Foreign Investment Company (new) — uniQure was a PFIC for the 2024 taxable year, triggering adverse U.S. tax consequences for U.S. holders; PFIC status may recur in future years.
NASDAQ: QURE uniQure N.V. 424B5

uniQure prices $225M IPO at $45.50/share, plans Q3 2026 BLA submission for AMT-130

Filed June 24, 2026 · ~2 min read

Offering filing cluster

Same offering
  1. 424B5 Jun 22, 2026 uniQure prices offering of ordinary shares and pre-funded warrants at $44.39/share; size redacted EDGAR →
  2. 424B5 Jun 24, 2026 This filing EDGAR →
  3. 8-K Jun 24, 2026 uniQure prices $243M equity offering, issuing 5.7M shares at $45.50 with full greenshoe EDGAR →

Key Changes

  • high

    uniQure priced 4,945,055 ordinary shares at $45.50/share, raising $225.0M gross for the company (before underwriting discount). The implied post-offering market capitalization is $3.1B.

    The Offering verify on EDGAR →
  • high

    The company plans to submit a BLA for AMT-130 in Huntington's disease in Q3 2026 following FDA feedback that three-year Phase I/II data would support accelerated approval. FDA requires alignment on a confirmatory study design (without sham procedure) and expects the study underway before BLA approval.

    Risk Factors verify on EDGAR →
  • high

    New investors pay $45.50/share for stock with $3.78 net tangible book value per share after the offering, suffering immediate dilution of $41.72/share (91.7%). An additional 11.3M shares are reserved for equity awards and warrants, with outstanding options at a $15.90 weighted average exercise price.

    Dilution verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FDS 10-Q) is open in full — no account needed.

Partner

Trade QURE commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Source-verified from EDGAR · Narrative written by AI · Jul 7, 2026 · How we verify